Treating and finding ways to better cure a person living with cancer is both a serious and challenging task that requires the most keen of minds and a stout emotional fortitude. Mikhail Blagosklonny has both of these qualities in spades. His vision is daring and ambitious, as he intends to find the ways for mankind to not only live better without the affliction of cancer but also longer and healthier lives.
So far, he has the experience of extensive research and understudy under his belt. But now, he feels it is time that medical knowledge finally bridge the gap between age and cancer to realize that the human condition just may not have to deal with one while slowing the other. In the quest for knowledge and a medical breakthrough of the ages, his efforts lead him to be a professor in the science of oncology at Roswell Park Institute. However, he is more than just the wise man of that mountain in one respect, because on top of his professional duties within the institution of education he holds the position of Editor-in-Chief of Oncotarget. And even though Mikhail Blagosklonny is kind of a big deal to fellow academicians, professional colleagues, and other scientific minds scattered far and wide, he is taken aback by a few things. View his LinkedIn profile.
One such subject is the pharmaceutical Rapamycin, and it deserves a bit of a spotlight itself. This because it has so many properties and uses in the medical field, along with an interesting history in tow. Its origins is as an antifungal agent extracted from a bacteria found on the easter islands. Today it is used as an immunosuppressant, which aids in transplants. There are also a number of other ailments this drug helps to combat such as hemolytic-uremic syndrome and Lymphangioleiomyomatosis. It also does wonders for coronary stent coating, which is needed after a balloon angioplasty.
In studies conducted, evidence shows that Rapamycin injected into laboratory mice helps aging specimens in their recover from tuberculosis. In humans the drugs boosts immune systems before the administration of a shot. This particular experiment shows a reaction in elderly patients, but there is no solid proof that Rapamycin directly slows the process. But even if this is not true, there are a number of other studies in the works that may still find a miracle use for this drug. These studies sfre for Alzheimer’s, Muscular Dystrophy and Systemic Lupus Erythematosus. If there there is a way to use Rapamycin to cure the diseases, then Mikhail Blagosklonny is just the professor and Editor-in-Chief to find the connections. Know more about Mikhail at Onmogul.com.